Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Regeneron Pharmaceuticals, Inc
Femme et Homme Max 99 ans
Regeneron Pharmaceuticals, Inc
MAJ Il y a 5 ans
A study to assess the efficacy and safety of Dupilumab in patients with severe atopic dermatitis (AD) that are not controlled with oral cyclosporine A (CSA) or for those who cannot take oral CSA because it is not medically advisable
To evaluate the efficacy of 2 dose regimens of dupilumab compared to placebo, administered with concomitant topical corticosteroids (TCS), in adult patients with severe AD who are not adequately contr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Regeneron Pharmaceuticals, Inc
MAJ Il y a 5 ans
Efficacy and Safety of REGN727/SAR236553 in patients with primary hypercholesterolemia who are intolerant to statins
The primary objective of the study is to demonstrate the reduction of low-density lipoprotein (LDL) cholesterol (LDL-C) by REGN727 in comparison with ezetimibe (EZE) 10 mg PO QD after 24 weeks in pati...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Regeneron Pharmaceuticals, Inc
MAJ Il y a 5 ans
A Double-Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema (DME)
To explore the effect of various doses and dose intervals of intravitreally (IVT)-administered VEGF Trap-Eye on the best-corrected ETDRS visual acuity (BCVA) in subjects with DME.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Regeneron Pharmaceuticals, Inc
MAJ Il y a 5 ans
A study to confirm the efficacy and safety of different dupilumab dose regimens in adults with atopic dermatitis (AD)
The primary objective of the study is to assess the ability of different dupilumab dose regimens, administered as monotherapy, to maintain the treatment response achieved after 16 weeks of initial tre...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Regeneron Pharmaceuticals, Inc
MAJ Il y a 5 ans
A study to determine the long-term safety and the efficacy of fasinumab for treatment of adults with pain from osteoarthritis of the knee or hip
To evaluate the long-term joit safety of fasinumab compared with placebo when administered in patients with pain due to radiographically confirmed OA in the knee or hip
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Regeneron Pharmaceuticals, Inc
MAJ Il y a 5 ans
A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy
To determine the efficacy of 160 mg and 80 mg of subcutaneous (SC) rilonacept therapy compared to placebo in the prophylaxis of flares in subjects with intercritical gout initiating therapy with allop...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Regeneron Pharmaceuticals, Inc
MAJ Il y a 5 ans
A study to assess the long-term safety and efficacy of dupilumab administered in patients 6 to <18 year of age with atopic dermatitis (eczema)
The primary objective of the study is to assess the long-term safety of dupilumab in pediatric patients with AD.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Regeneron Pharmaceuticals, Inc
MAJ Il y a 5 ans
A study to see if multiple doses of REGN668 given by injections under the skin is effective, safe and how it acts in the body of adult patients with moderate-to-severe atopic dermatitis caused by allergic response
The primary objective is to assess the clinical efficacy of repeated subcutaneous (SC) doses of REGN668 in adult patients with moderate-to-severe atopic dermatitis (AD).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Regeneron Pharmaceuticals, Inc
MAJ Il y a 5 ans
A study to determine the efficacy and safety of fasinumab for the treatment of adults with lower back pain
To evaluate the efficacy of fasinumab compared to placebo as measured by the change from baseline in the average daily low back pain intensity (LBPI) NRS score.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Regeneron Pharmaceuticals, Inc
MAJ Il y a 5 ans
A study to determine if REGN727 will have an effect of circulating lipids in patients with gain-of-function mutations in their PCSK9 gene
To assess the effect of REGN727 on serum Low-density lipoprotein cholesterol in patients with autosomal domianant hypersholesterolemia and gain-of-function mutations in the PCSK9 gene.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
1
2
3
Suivant